XML 23 R6.htm IDEA: XBRL DOCUMENT v3.19.1
CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2018
Dec. 31, 2017
Cash flows from operating activities:    
Net loss $ (27,670) $ (23,754)
Adjustment to reconcile net loss to net cash used in operating activities:    
Gain on extinguishment of debt (766) 0
Non-cash In-process research and development impairment charge 9,100 0
Non-cash interest expense 134 0
Amortization of research and development expense 0 258
Deferred income taxes (1,316)  
Non-cash stock-based compensation 395 3,169
Fair value of common stock issued in exchange for services 0 449
Fair value of common stock issued in connection with litigation settlements 1,250 0
Fair value of common stock issued in connection with litigation settlements 0 941
Change in fair value of common stock warrants (5,302) 0
Change in fair value of contingent consideration 3,032 0
Loss on settlement of liability-classified warrants 727 0
Severance costs paid by Galena 0 1,883
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 212 73
Accounts payable (7,936) 8,366
Accrued expenses and other current liabilities (2,282) (2,374)
Net cash used in operating activities (30,422) (10,989)
Cash flows from investing activities:    
Net cash acquired from acquisition of Galena 0 12,158
Net cash used from investing activities 0 12,158
Cash flows from financing activities:    
Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs 9,647 0
Proceeds from issuance of common stock, net of issuance costs 21,564 6,007
Dividends paid (487) 0
Principal payments on long-term debt (7,601) (473)
Net cash provided by financing activities 23,123 5,534
Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents (7,299) 6,703
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the beginning of period 12,750 6,047
Cash, cash equivalents, restricted cash, and restricted cash equivalents at the end of period 5,451 12,750
Supplemental disclosure of cash flow information:    
Cash received during the periods for interest 186 0
Cash paid during the periods for interest 321 0
Supplemental disclosure of non-cash investing and financing activities:    
Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost 5,530  
Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock 4,436 0
Repayment of interest and principal on long-term debt through issuance of common stock 3,721 0
Reclassification of warrant liabilities upon exchange for shares of common stock 285 0
Impact of anti-dilution protection on liability-classified warrants 491 0
Debt issued in connection with warrant exchange agreements 966 0
Shares issued in connection with acquisition of Galena 0 12,487
Fair value of options assumed in connection with acquisition of Galena 0 32
Related party payable settled in shares 0 228
Memorial Sloan Kettering Cancer Center payable settled in shares 0 150
Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria 0 675
Convertible Debt Two Thousand Fifteen Shareholder Notes    
Supplemental disclosure of non-cash investing and financing activities:    
Stock issued 0 1,294
Convertible Debt Two Thousand Sely Note    
Supplemental disclosure of non-cash investing and financing activities:    
Stock issued $ 0 $ 6,064